Latest osteosarcoma Stories
INDIANAPOLIS, July 23 /PRNewswire-FirstCall/ -- Today, Eli Lilly and Company (NYSE: LLY) announced that the U.S.
SAN MARINO, Calif., June 22 /PRNewswire/ -- Epeius Biotechnologies (www.epeiusbiotech.com) stuns the medical and scientific communities with a dramatic demonstration of single-agent efficacy with its lead product, Rexin-G, for metastatic cancer.
A grant from the Liddy Shriver Sarcoma Initiative will allow Dr. Pulivarthi Rao, associate professor of pediatrics at Baylor College of Medicine, and his team of researchers to explore the role of the gene CDC5L in the development of osteosarcoma, the most common bone cancer in children.
SAN MARINO, Calif., May 18 /PRNewswire/ -- Epeius Biotechnologies (www.epeiusbiotech.com) today announced the results of two related studies using Rexin-G, a tumor-targeted anti-cancer agent designed to seek-out and destroy metastatic cancers that have spread throughout the body.
OSAKA, Japan, and IRVINE, Calif., May 18 /PRNewswire-FirstCall/ -- Takeda Pharmaceutical Company Limited (TSE: 4502) and IDM Pharma, Inc.
HUNTSVILLE, Ala., May 5 /PRNewswire/ -- Osteosarcoma is the most common and potentially most dangerous bone cancer. It primarily affects young people between the ages of 10 - 25. In "Cancer from A to Z" (published by AuthorHouse), a new cancer dictionary by Dr.
NEW YORK, April 29 /PRNewswire-USNewswire/ -- Blood fluoride levels were significantly higher in patients with osteosarcoma than in control groups, according to research published in Biological Trace Element Research (April 2009).
First New Agent Approved to Treat Osteosarcoma in More Than 20 Years IRVINE, Calif., March 9 /PRNewswire-FirstCall/ -- IDM Pharma, Inc.
IRVINE, Calif., Feb.
SAN MARINO, Calif., Feb.
- A gift; a largess; a gratuity; a present; a dole.